[The Relationship between Body Mass Index and Adult Acute Myeloid Leukemia].
摘要
OBJECTIVE: To analysis the relationship between different BMI (body mass index) and the clinical characteristics, laboratory examination indexes of newly diagnosed adult patients with acute myeloid leukemia (AML), so as to investigate the effects of BMI to the efficacy of first induction chemotherapy. METHODS: ) of the selected AML patients before induction chemotherapy was calculated and the patients were divided into the low body mass group (BMI<18.5), the normal body mass group (18.5 ≤BMI ≤23.9) and the overweight and obese group (BMI ≥24). The clinical data of the patients, including sex, age, risk stratification,the types of leukemia, gene mutation, complications, length of hospital stay and other clinical features; white blood cell (WBC), hemoglobin (Hb), albumin, triglyceride (TG), total cholesterol (TC), high-density lipoprotein (HDL), low density lipoprotein (LDL), lactate dehydrogenase (LDH), and other laboratory index; agra-nulocytosis with fever, infection of etiology, lack of granulocyte duration, significant bleeding, liver and kidney toxicity of chemotherapy adverse reactions associated indicators and Morphological remission were collected. The induction chemotherapy regimen was the standard chemotherapy regimen (anthracyclines combined with cytarabine). RESULTS: /L showed lower CR rate, but there was no statistical difference in the patients of each group. CONCLUSION: In newly diagnosed adult patients with AML, low body mass, overweight and obesity, and FLT3 mutations were the factors reducing the early efficacy of AML patients. There were more adverse reactions induced by chemotherapy in the low body mass group. Therefore, inappropriate BMI level can be a risk factor for assessing the prognosis of adults with newly diagnosed AML.